2026年2月9日 美国东部时间下午3:59 / 路透社
（图片说明：2020年8月29日，美国马里兰州怀特橡树的美国食品药品监督管理局（FDA）总部外可见标识。路透社/Andrew Kelly/资料图片）
2月9日（路透社）- 根据2月5日发出的一封信，美国食品药品监督管理局（FDA）称诺和诺德公司的减肥药物电视广告”虚假或具有误导性”。
该卫生监管机构表示，该电视广告误导性地暗示， Wegovy（口服片剂形式）相较于其他属于GLP-1类别的减肥药物具有进步或改进。
订阅路透社健康动态通讯，获取最新的医疗突破和医疗趋势。点击此处注册。
诺和诺德发言人安布尔·詹姆斯-布朗表示：”我们确认，诺和诺德收到了FDA关于Wegovy片剂电视广告的’无题信’，该广告自推出以来一直在播放——而非超级碗广告。”
广告 · 继续滚动阅读
FDA称，诺和诺德的直接面向消费者广告违反了《联邦食品、药品和化妆品法案》，并要求该制药商立即采取行动纠正任何违规行为，其中可能包括停止所有包含误导性声明的广告。
詹姆斯-布朗补充道：”我们高度重视所有监管反馈，正在回应FDA的关切，以解决他们对广告呈现方式的疑虑。”
FDA还指出，广告中的宣传语”更轻松生活”和”前进之路”误导性地暗示，与目前获批的其他GLP-1类治疗方法相比，Wegovy能带来额外的体重减轻效果，而这一点尚未得到证实。
广告 · 继续滚动阅读
FDA在信中表示：”此外，这些宣传语还误导性地暗示该药物除了身体减重之外还有其他益处，如情绪缓解、减轻心理负担、带来希望或为患者生活指明方向，将药物定位为解决更广泛生活挑战的方案，而非针对特定病症的治疗方法，而这也未得到证实。”
FDA还指出，该广告包含某些画面中文字与音频不符的情况。
路透社记者斯里帕纳·罗伊（Sriparna Roy）报道；维贾伊·基肖尔（Vijay Kishore）和艾伦·巴罗纳（Alan Barona）编辑
US FDA says Novo’s obesity pill TV ad is false or misleading
February 9, 2026 3:59 PM UTC / Reuters
节点运行失败
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
Feb 9 (Reuters) – The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk’s weight-loss pill is “false or misleading,” according to a letter dated February 5.
The health regulator said the television spot misleadingly suggests that Wegovy, in its pill form, offers an advancement or improvement over other weight-loss drugs that belong to the class known as GLP-1s.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
“We confirm that Novo Nordisk received an ‘Untitled Letter’ from FDA concerning a television commercial for Wegovy pill, which has been running since launch — not the Super Bowl ad,” said Novo spokeswoman Ambre James-Brown.
Advertisement · Scroll to continue
The agency said the Novo direct-to-consumer ad was in violation of the Federal Food, Drug, and Cosmetic Act, and asked the drugmaker to take immediate action to address any violations, which could include ceasing all ads containing misleading claims.
“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” James-Brown added.
The FDA also said the claims “live lighter” and “a way forward” misleadingly imply additional weight loss compared to other currently approved GLP-1 treatments, when this has not been demonstrated.
Advertisement · Scroll to continue
“Additionally, they misleadingly imply benefits beyond physical weight loss, such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives, positioning the drug as a solution to broader life challenges rather than a treatment for a specific condition, when this has also not been demonstrated,” the agency said in the letter.
The FDA also flagged the ad included certain presentations where the text on screen did not match the audio.
Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore and Alan Barona
发表回复